1Flu vaccine comparison chart© 2021 Vizient, Inc. All rights reserved.

2021-2022

Flu vaccine comparison chart

2Flu vaccine comparison chart© 2021 Vizient, Inc. All rights reserved.

About this guideThis guide provides information about the seasonal influenza vaccine products that are anticipated to be available during the 2021-2022 influenza season. It has been prepared using 2020-2021 product package inserts submitted by manufacturers to the US Food and Drug Administration (FDA) and housed within the DailyMed database. For the 2021-2022 influenza season, all influenza vaccine formulations will be quadrivalent, including Fluad. Only Afluria will be available in a 0.25 mL (pediatric) prefilled syringe. No other changes are expected. The information contained in this guide is current as of June 2021.

0-6 months 6-23 months 2-17 years 18-49 years 50-64 years ≥65 years

Afluria, Fluarix, FluLaval, Fluzone

Flucelvax

Fluad

Fluzone High-Dose

Flublok

FluMist

Influenza vaccines by age for the 2021-22 influenza season

Adapted from CDC https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-influenza-grohskopf-508.pdf

3Flu vaccine comparison chart© 2021 Vizient, Inc. All rights reserved.

AfluriaSeqirus

FluadSeqirus

FlucelvaxSeqirus

Fluarix GlaxoSmithKline

FlulavalGlaxoSmithKline

Fluzone Sanofi Pasteur

FlublokSanofi Pasteur

FluMist Astra Zeneca

Description Quadrivalent, inactivated

Quadrivalent, inactivated (adjuvant)

Quadrivalent, inactivated

Quadrivalent, inactivated

Quadrivalent, inactivated

Quadrivalent, inactivated

Quadrivalent, recombinant

Quadrivalent, Live attenuated - intranasal

Manufacturing process

Egg-based Egg-based Cell culture: MDCK cells (egg free)

Egg-based Egg-based Egg-based Cell culture: insect cells (egg free)

Egg-based

Prefilled syringe 0.25 mL (peds)

0.5 mL

0.5 mL 0.5 mL 0.5 mL 0.5 mL 0.5 mL (Fluzone)

0.7 mL (Fluzone HD)

0.5 mL 0.2-mL intranasal sprayer

Vial 5 mL MDV – 5 mL MDV – – 0.5 mL SDV (Fluzone)

5 mL MDV (Fluzone)

– –

Latex Latex-free Latex-free Latex-free Latex-free Latex-free Latex-free Latex-free Latex-free

Mercury per 0.5-mL dose

MDV: 24.5 mcg – MDV: 25 mcg – – MDV: 25 mcg – –

Ovalbumin per 0.5 mL dose

< 1 mcg ≤ 1 mcg – ≤ 0.05 mcg ≤ 0.3 mcg Information not provided

– < 0.024 mcg per

0.2-mL dose

Formaldehyde per 0.5-mL dose

– ≤ 10 mcg – ≤ 5 mcg ≤ 25 mcg Fluzone: ≤100 mcg

Fluzone HD: ≤140 mcg

– –

Antibiotics per 0.5-mL dose

Neomycin ≤ 81.8 ng polymyxin B ≤14 ng

Neomycin (≤ 0.02 mcg by calculation) kanamycin; (≤ 0.03 mcg by calculation)

– May contain residual amounts of gentamicin ≤0.15 mcg

– – – Gentamicin (< 0.015 mcg/mL) per 0.2-mL dose

HA per A and B strains in each 0.5-mL dose

15 mcg HA 15 mcg HA (MF59 adjuvant)

15 mcg HA 15 mcg HA 15 mcg HA Fluzone: 15 mcg HA

Fluzone HD: 60 mcg HA

45 mcg HA Each 0.2 mL dose contains 10 6.5-7.5 fluorescent focus units of live attenuated influenza strain for each of the 4 strains

Approved population

≥ 6 mo ≥ 65 y ≥ 2 y ≥ 6 mo ≥ 6 mo Fluzone: ≥ 6 mo

Fluzone HD: ≥ 65 y

≥ 18 y 2-49 y

Pregnancy recommendations per ACIP

Pregnant women are at increased risk of severe illness due to influenza; those who contract influenza may be at increased risk for adverse pregnancy outcomes, including preterm labor and delivery.

ACIP and the American College of Obstetricians and Gynecologists recommend that all women who are pregnant or who might be pregnant or postpartum during the influenza season receive an influenza vaccine.

Pregnant women receiving an influenza vaccine should be enrolled in that vaccine product’s pregnancy exposure registry (specified in package inserts).

Avoid in pregnancy per CDC.

Dosing General dosing recommendations for injectable vaccine (refer to individual vaccine information for more information). Children aged 6 months through 8 years require 2 doses of influenza vaccine administered a minimum of 4 weeks apart during their first season of vaccination for optimal protection. Those children >9 who have not previously received ≥2 doses of influenza vaccine ≥4 weeks apart, or whose previous influenza vaccination history is unknown, require 2 doses for the season (source: ACIP recommendations, 2020-2021 influenza season)

2-8 y: Give 1 or 2 doses of 0.2 mL eacha

9-49 y: Give 1 dose of 0.2 mL

Each 0.2-mL dose should be divided equally between both nostrils (0.1 mL per nostril)

Contraindications History of severe allergic reactions (e.g., anaphylaxis) to any component of vaccines, including egg protein, or following a previous dose of any influenza vaccine (Afluria, Fluad)

Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine

History of severe allergic reactions (e.g., anaphylaxis) to any component of vaccines, including egg protein, or following a previous dose of any influenza vaccine (Fluarix, FluLaval, Fluzone)

Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine

Severe allergic reaction to any component (inc. egg protein) or to any previous influenza vaccine; avoid in ages 2-17y on aspirin

2021-22 influenza vaccines product comparison guide

Age

6-35 mo

36 mo-8 y

≥ 9 y

Dose

1 or 2 doses; Afluria pediatric (0.25 mL) or Flulaval/Fluarix/Fluzone 0.5 mLa or Flucelvax 0.5 mL if ≥ 24 mo

1 or 2 doses; 0.5 mL eacha

1 dose; 0.5 mL

Schedule

If 2 doses, administer at least 1 mo apart (same seasonal vaccine)

If 2 doses, administer at least 1 mo apart (same seasonal vaccine)

–

4Flu vaccine comparison chart© 2021 Vizient, Inc. All rights reserved.

AfluriaSeqirus

FluadSeqirus

FlucelvaxSeqirus

Fluarix GlaxoSmithKline

FlulavalGlaxoSmithKline

Fluzone Sanofi Pasteur

FlublokSanofi Pasteur

FluMist Astra Zeneca

Storage requirements

Store between 2°C to 8°C (36°F to 46°F).

Protect from light.

Discard if vaccine has been frozen.

Between uses, return MDV to recommended storage conditions.

Once the stopper of the MDV has been pierced it must be discarded within 28 days.

The number of needle punctures should not exceed 20 per MDV.

Store between 2°C to 8°C (36°F to 46°F).

Protect from light.

Discard if vaccine has been frozen.

Store between 2°C to 8°C (36ºF to 46ºF).

Between uses, return the MDV to the recommended storage conditions.

Do not freeze.

Protect from light.

Store between 2ºC and 8ºC (36ºF and 46ºF).

Discard if the vaccine has been frozen.

Store in the original package to protect from light.

Store between 2º and 8ºC (36ºF and 46ºF).

Discard if the vaccine has been frozen.

Store in the original package to protect from light.

Store all Fluzone Quadrivalent presentations between 2°C to 8°C (35°F to 46°F).

Discard if vaccine has been frozen.

A maximum of ten doses can be withdrawn from the MDV.

Store between 2°C and 8°C (36°F and 46°F).

Do not freeze. Discard if product has been frozen.

Protect syringes from light.

Maintain cold chain [2-8°C (35-46°F)] when transporting.

Store between 2ºC and 8ºC (35º and 46ºF). Do not freeze.

Keep sprayer in outer carton in order to protect from light.

A single temperature excursion up to 25°C (77°F) for 12 hours has no adverse impact on the vaccine. Return vaccine immediately to recommended storage conditions (2°C – 8°C) and used as soon as feasible. Subsequent excursions are not permitted.

Date on PI 8/2020 11/2020 7/2020 7/2020 7/2020 7/2020 7/2020 8/2020

a Refer to current seasonal influenza vaccination guidelines for more information. Fluzone has both an approval for a 0.25 mL dose and a 0.5 mL dose in children aged 6 months to 35 months as of January 23, 2019. Fluzone will not be supplied in a 0.25 mL prefilled syringe for the 2021-2022 influenza season. Health care practitioners wishing to administer a 0.25 mL dose will need to use the Fluzone single-dose vial

Abbreviations: GBS = Guillain-Barré syndrome; HA = hemagglutinin; HD = high-dose; MDCK = Madin-Darby canine kidney cells; MDV = multi-dose vial; PFS = prefilled syringe; PI = package insert; SDV = single-dose vial.

Updated: June, 2021

2021-22 influenza vaccines product comparison guide (cont.)

Vizient, Inc.

290 E. John Carpenter Freeway

Irving, TX 75062-5146

(800) 842-5146